"Compulsive eating", early onset obesity and cognitive impairments are among the most significant symptoms, as reported by ...

Zack D Films is back at it again, but this time, he's included a gross scene at the end of his clip to highlight Ozempic side ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

The drugmaker Eli Lilly this week said that tests of its GLP-1 pill could work just as well as injectable drugs like ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...